ClinicalTrials.gg
CompletedNCT06155019SWEEDUpdated Jan 10, 2025

Switch From Etravirine to Doravirine as a Part of Antiretroviral Combination

An observational study in HIV Infections, sponsored by Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-10.

Sponsored by Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
109
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 278 studies in HIV Infections with a site in France — 19 open to participants now, 27 under way, 5 of them phase 3. HIV Infections · France.

Enrollment
43rd of 59
109 · median 200
Started
2023
with 8 others
Observational
59 of 278
13 open now
Registered
261st of 278
by date
Lead sponsor
8 of 278
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida

Among the 278 studies in HIV Infections with a site in France, this one is the 43rd largest by enrollment of the 59 observational ones that give a count, is one of 9 that started in 2023, is one of 59 observational ones, and was the 261st registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

19 of the 278 studies in HIV Infections with a site in France are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 278 studies in HIV Infections with a site in France, or all of them as a file.
02

Study summary

The main objective of the SWEED study is to determine whether doravirine containing ART is able to maintain viral suppression at W48 in HIV-1 infected people living with HIV (PLWH) receiving etravirine containing ART:

  • An ARV strategy containing doravirine as a replacement for etravirine can maintain virological suppression in participants with controlled viral replication under ARV treatment containing etravirine, with a virological success rate >90%
  • This strategy can maintain virological suppression even in the event of NNRTI resistance mutations acquired in the past
  • This strategy is well tolerated
  • The emergence of resistance to NNRTIs is uncommon in the event of virological failure under the ARV regimen containing doravirine
Read the detailed description

The evolution of HIV infection from fatal to chronic has been enabled by advances in development and access of antiretroviral treatment (ART), which has also resulted in life expectancy of PLWH approaching that of those uninfected.In addition, over the past few years, new drugs and news regimens have offered improved efficacy, safety and tolerability. The 95-95-95 UNAIDS target, i.e. to diagnose 95% of PLWHIV (1st 95), provide ART to 95% of those diagnosed with HIV (2nd 95), and to reach viral suppression in 95% of patients on ART (3rd 95), is being achieved in several countries. Calls to add a fourth target, i.e. to improve the quality of life for PLWHIV, have grown stronger since the concept was introduced in 2016. The twin aims are long-term treatment durability and improved quality of life with a focus on personalized treatment.

Switching or simplifying ART in the setting of HIV suppression may improve pill burden, dosing frequency, safety, tolerability, and/or food requirements. At times, ART switch or simplification is elective, such as consolidating a multiple-tablet to a single-tablet regimen (STR). Other times, it is necessary to eliminate drug-drug interactions (DDIs) and/or minimize active or potential treatment-associated adverse events (AEs). The fundamental principle of switching or simplifying ART is to preserve virologic suppression without jeopardizing future ART options.

Etravirine, a second generation NNRTI, has been demonstrated to be effective on HIV strains with prior resistance mutations on reverse transcriptase impacting other NNRTIs, such as nevirapine, efavirenz or rilpivirine. It has even been used in salvage therapy, in association with darunavir and raltegravir, in uncontrolled patients with multiresistant strains. Etravirine is mostly prescribed twice daily, and is a strong enzymatic inducer providing many DDIs, complicating its use.

Doravirine, a last generation NNRTI, is approved in treatment-naïve and experienced HIV-infected individuals. In the DRIVE-FORWARD study, doravirine 100 mg QD, in combination with either TDF/FTC or ABC/3TC, achieved high virologic success at week 48 and was non-inferior to DRV/r + 2 NRTIs regardless of baseline HIV-RNA. In the DRIVE-AHEAD study, in treatment-naïve adults with HIV-1 infection, doravirine + 3TC/TDF administered once daily demonstrated a high antiviral potency with non-inferior efficacy to EFV/FTC/TDF regardless of baseline HIV-RNA, and a low rate of resistance, with only 1.6% of participants developing resistance to any study drug through W48. For virologically suppressed patients considering a change in therapy, switching to DOR/3TC/TDF was shown to be a well-tolerated option which was non-inferior to continuation of the previous regimen, with high rates of virologic suppression and low rates of virologic rebound. Long term results from the DRIVE-SHIFT trial showed that doravirine maintained virologic suppression and was generally well tolerated through 144 weeks of treatment. DOR/3TC/TDF as switch therapy showed a favorable lipid profile compared with previous regimens and results in minimal weight gain. The convenience achieved through switching to a DOR based regimen serves to achieve regimen simplification and could respond to patient demands for increased tolerability.

The DOR resistance profile is distinct from that of other NNRTIs with the in vitro selection of mutations at reverse transcriptase (RT) positions 106, 108, 188, 227, 230, 234 and 236. In vitro studies have also suggested that DOR has activity against viruses with certain mutations selected by other NNRTIs, including the K103N and Y181C mutations. In the DRIVE-SHIFT trial, conducted in virologically suppressed patients, 24 participants had a virus with baseline NNRTI mutations (K103N, Y181C and G190A) and 23/24 who switched to DOR/3TC/TDF remained virologically suppressed at the 48-week follow-up. This suggests that the most frequent NNRTI mutations at RT mutation positions 103, 181 and 190 probably not impact DOR activity in vivo.

Due to its virological properties, we believe that doravirine can advantageously replace etravirine, maintaining control of viral replication, in combination with other antiretrovirals, in virologically controlled patients, despite possible exposure to NNRTIs in the pass. Furthermore, doravirine is taken as a single tablet once a day, and causes almost no drug interactions, unlike etravirine.

03

Conditions studied

  • HIV Infections

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This observational, non-interventional, multicenter study will assess the efficacy of switching etravirine to doravirine in virally suppressed PLWH on stable etravirine containing ART, with at least 48 weeks of follow-up

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients over 18 years
  • With -1 infection
  • On a regimen containing etravirine QD or BID combined with at least one other antiretroviral from any class except NNRTI
  • Who had switched for a regimen containing doravirine combined with the same number of other antiretrovirals
  • With plasma HIV-RNA \<50 copies/mL for at least 12 months (one blip \<200 copies/mL permitted) at time of switch to doravirine
  • With at least 2 available pVL after the switch, and at least 48 weeks between the switch and the last available pVL*
  • Who gave their non-opposition for the study

    • For patients who stopped doravirine-based treatment or were lost to follow-up before 48 weeks, only the theoretical duration of follow-up will be taken into account (time between the switch and the date of analysis)

Exclusion criteria

Exclusion Criteria:

  • Subject under " sauvegarde de justice " (judicial protection due to temporarily and slightly diminished mental or physical faculties), or under legal guardianship
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
109 participants (actual)
Patient registry
No

Groups and cohorts

  • Non comparative

    switch from etravirine to doravirine, with no change in associated antiretroviral drugs, will be assessed retrospectively

06

What researchers measure

Primary outcomes

  1. Measure the virological efficacy at week 48 a doravirine-containing ART to assess the effectiveness of the switch to maintain the virological success to W48

    Measure of plasma viral load assessed by RNA quantification using COBAS 6800 system (Roche)

    Time frame: 12 months

07

Study locations

1 site
  • Pitié-Sapêtrière Hospital
    Paris, 75013, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in May 2024, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2023
First posted
Dec 4, 2023
StartActual
Dec 8, 2023
Primary completionActual
May 31, 2024
CompletionActual
Sep 15, 2024
Last update
Jan 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06155019
Lead sponsor
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
Responsible party
Sponsor
First posted
Dec 4, 2023
Start date
Dec 8, 2023
Primary completion
May 31, 2024
Completion
Sep 15, 2024
Last update
Jan 10, 2025

Study contacts

Romain PALICH, DR
principal investigator · Pitie-Salpetriere Hospital, Infectious Diseases department

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion